Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.
CannTrust Holdings (CTST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Eisai (ESALY).